Last updated
Teva Pharmaceuticals: M&A Activity
Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices
Source: Endpoints News
- Who
- Teva Pharmaceuticals · Biotech & Pharma · USA
- What happened
- Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices
- When
- 2026-08-06
- Source
- Endpoints News
Market context: This lands while the Talent Market Index reads 95.4 (Cool) — down 5.3 versus the prior month — and Americas signal share is easing (-16.2pts).
Teva Pharmaceuticals: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 31 tracked companies; 0.1% of MitchelLake's Oceania signal flow; 4 tracked across 50 days.
MitchelLake in this thematic
Also at Teva Pharmaceuticals →
More signals across Biotech & Pharma
M&A Activity · Americas
Repligen Corporation →Repligen completed acquisition of BioLife Solutions for $11.25/share cash plus stock consideration. Transaction consolidates cell therapy bioprocessing capabilities and expands Repligen's product portfolio in high-growth cell and gene therapy market.
M&A Activity · Americas
Amgen →Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.
M&A Activity · Americas
BioMarin Pharmaceutical Inc. →BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.
M&A Activity · Americas
Biogen →Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.
M&A Activity · Americas
Bristol Myers Squibb →Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal
M&A Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Where this lands in our work
- Private Equity →
Ownership change resets the executive requirement — value-creation leadership follows the deal.
- Executive Search: Americas →
Our Americas practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record
